6 results
To demonstrate that the infliximab serum concentration of Remsima* is non-inferior to the infliximab serum concentration of Remicade , 16 weeks after switch from Remicade to Remsima* in subjects with CD, UC or RA in stable remission for > 30…
Primary: To evaluate the long-term safety of repeated subcutaneous(SC) administrations of lanadelumab in adolescents and adults with nonhistaminergicangioedema with normal C1-INH
Primary: To evaluate the efficacy of repeated subcutaneous (SC) administrations of lanadelumab in preventing angioedema attacks in adolescents (12 to <18 years of age) and adults with non-histaminergic angioedema with normal C1-INH.Secondary…
The objectives of this study:• To generate the proof of concept for lanadelumab for treatment of symptoms of COVID-19 disease • To demonstrate its safety after intravenous administration.
In this prospective observational data-collection study with retrospective data analysis, 80 subjects, who have been admitted at the UMC Utrecht because of a surgery, will be recruited at the pre-operative screening clinic before surgery. Prior to…
The primary objective is to evaluate the accuracy of the SpO2 measurements by the ViQtor compared to matched SaO2 measurements obtained during a hypoxic measurements to obtain the root mean square (ARMS) for a range of skin types defined by…